Morphic Holding, Inc.

25.05 USD
+0.10 (+0.40%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Morphic Holding, Inc. stock is up 18.33% since 30 days ago. The next earnings date is Feb 22, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 60% of the previous 4 December’s closed higher than November. In the last 2 Unusual Options Trades, there were 1 PUT, 1 CALL.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
11 Oct 19:11 20 Oct, 2023 20.00 PUT 400 2865
12 Oct 13:36 20 Oct, 2023 25.00 CALL 615 1178

About Morphic Holding, Inc.

Morphic Holding, Inc. discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical trial for the. treatment of inflammatory bowel disease; and preclinical trial to treat idiopathic pulmonary fibrosis. and fibrosis diseases. The company is also developing avß6 and avß8 to treat solid tumors.